Business Context and Reporting Period
This Form 8-K Current Report was filed by Novavax, Inc. on April 25, 2025. The filing addresses a corporate governance event: the appointment of a new member to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on director appointments and compensation arrangements rather than financial performance.
Material Changes
- Board Expansion: The Board of Directors increased its size from eight to nine members.
- New Appointment: Charles W. Newton was appointed as a Class III director, effective April 25, 2025. His term expires at the 2025 annual meeting of stockholders.
- Independence: The Board determined Mr. Newton qualifies as independent under Nasdaq listing standards.
Guidance, Outlook, and Compensation Details
There is no guidance, outlook, or management commentary regarding business operations or risks in this filing. The document details the compensatory arrangements for the new director:
- Cash Compensation: Eligible under the Company's Non-Employee Director Compensation Policy as described in the 2024 Proxy Statement.
- Initial Equity Grant: On April 25, 2025, Mr. Newton received an initial grant with an aggregate fair value of approximately $525,000. This consists of:
- Options to purchase 42,840 shares of common stock.
- 28,560 restricted stock units (RSUs).
- Vesting Schedule: The initial grant vests in three equal annual installments over three years, contingent on continued service.
- Future Grants: Annual equity grants of approximately $350,000 will be awarded beginning at the 2026 second quarter Board meeting, vesting in full on the first anniversary.
- Indemnification: Mr. Newton is expected to enter into the Company's standard indemnification agreement.
Investor Verification Checklist
- Verify the total number of outstanding shares and the impact of the 42,840 new options and 28,560 RSUs on dilution.
- Review the Company's Definitive Proxy Statement on Schedule 14A (filed April 29, 2024) for details on the cash compensation policy referenced.
- Confirm the vesting conditions and potential forfeiture clauses associated with the new director's equity grants.
- Check subsequent filings for the formal execution of the standard indemnification agreement.